Back to top
more

Immunocore (IMCR)

(Real Time Quote from BATS)

$36.78 USD

36.78
147,779

-0.34 (-0.92%)

Updated Aug 27, 2026 03:45 PM ET

After-Market: $36.80 +0.02 (0.05%) 4:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises

by Zacks Equity Research

Esperion posts narrower-than-expected second-quarter loss with revenues rising 12% and product sales jumping 42% year over year.

Zacks Equity Research

JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut

by Zacks Equity Research

Jazz shares slide as Q2 loss widens on Chimerix charge, with 2025 sales outlook trimmed despite higher EPS guidance.

Zacks Equity Research

CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption

by Zacks Equity Research

CRISPR Therapeutics posts a wider second-quarter loss tied to Sirius deal costs, while Casgevy adoption gains momentum across global markets.

Zacks Equity Research

ZTS Q2 Earnings & Revenues Beat Estimates, '25 Outlook Raised

by Zacks Equity Research

Zoetis posts better-than-expected Q2 results with rising sales of pet medicines, boosting its 2025 outlook.

Zacks Equity Research

TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line

by Zacks Equity Research

TG Therapeutics slides 18% as second-quarter earnings fall short despite a 92% revenue jump fueled by surging Briumvi sales.

Zacks Equity Research

AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y

by Zacks Equity Research

Axsome posts narrower second-quarter loss and 72% revenue surge, driven by strong Auvelity sales.

Zacks Equity Research

VRTX Q2 Earnings Beat, Stock Down as Pain Drug Misses Study Goal

by Zacks Equity Research

Vertex beats second-quarter earnings and revenue estimates, but shares slide as pain drug VX-993 misses study goal.

Zacks Equity Research

BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View

by Zacks Equity Research

BMRN's Q2 earnings surge 50% on strong Voxzogo and enzyme therapy sales, prompting a raised 2025 revenue and EPS outlook.

Zacks Equity Research

KRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 Outlook

by Zacks Equity Research

Krystal Biotech tops Q2 estimates with strong Vyjuvek sales, but shares fall 14% on weak Q3 revenue guidance.

Zacks Equity Research

CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down

by Zacks Equity Research

Corcept beats second-quarter earnings forecasts but misses the same for revenues. The company trims its 2025 revenue outlook.